TrumpLyftAlles | 2 points
Mountain Valley MD Files Patent to Protect Science Achievement in Solubilization of Ivermectin Without Organic Solvents and tts Application to Covid-19 and Other Therapies (Canada 2020-11-11) For injection, oral consumption and inhalation[-] Low-Dog8582 | 1 points
From the October 2nd news release:
“Ivermectin is a typical lipophilic BCS class 2 drug with poor water solubility and poor absorption allowing for only a very limited bioavailability,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD. “We believe the ability to dose ivermectin in both an oral microparticle and a mucoadhesive strip form with our QuicksomeTM technology will help to dramatically improve the efficacy of the drug.”
"With the successful dosing of these two product forms, the Company anticipates receiving the complete pharmacokinetic data from the ivermectin pre-clinical trials within the next two weeks. It is anticipated that the pharmacokinetic data will successfully document superior movement of the ivermectin drug into, through, and out of the body and the time course of its absorption, bioavailability, distribution and metabolism."
- It's great that MVMD discovered a technique they believe is patentable for making ivermectin water-soluble without the use of organic solvents while they were pursuing the pre-clinical trials, but I want more information on these trials. Clearly they have the pharmacokinetic data as its been five and a half weeks and they anticipated receiving this data within two. Did the QuicksomeTM tech show superior movement of the ivermectin drug into, through, and out of the body....?
I am not familiar with analyzing pharma companies, but is it normal for a company to withhold this data? To not even mention whether the trial was successful or even comment at all on the preclinical trials? When you say you will have the pharmacokinetic data within 2 weeks and then have radio silence for five and a half investors start getting a little curious. This news release was clearly not what investors wanted. We see a lot of 'may', 'potentially', believe' and COVID-19. Rarely do you have a news release announcing a new patent and a major selloff in the stock. Investors have been waiting patiently for an update on the QuicksomeTM tech and its efficacy in the pretrials. This Michael Farber guy that they bought the patents from and who now works for MVMD has had these patents for quite sometime. Its curious why this insight was just realized now during a pretrial trying to demonstrate the efficacy of a different patent. How is this discovered during the pretrial? You would think that during the pretrial they are not experimenting with other novel ways to make ivermectin water soluble.
[-] No-Sandwich-777 | 1 points
I do not advocate any of this, but people have been vaping propylene glycol solutions for years.
A little spritz? Why have these quacks formulate it?
[-] No-Sandwich-777 | 1 points
Nasal introduction is being experimented with many therapeutics.
https://www.researchsquare.com/article/rs-25854/v1
There are many more that I do not mention. MicroRNA, other SiRNA routes. We will see a bunch. We are headed to a dark time in Autumn, Winter, and Spring. Darker than you ever thought. The virus and it's treatment have evolved, but the ability to treat in a hospital setting will grow out of control.
Wear your PPE people, and stop looking for an instant cure. Viruses are hard to handle, and there seems to be good data on the mRNA vacs, as well as more traditional models.
This will take years to overcome when you look at the logistics. Do not let your guard down!
[-] TrumpLyftAlles | 1 points | Nov 11 2020 11:50:28
Unfortunately this will have to jump through the FDA's approval process, so probably won't arrive before the vaccines do.
Vancouver, B. C. - TheNewswire - November 11, 2020 - Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE:MVMD) (CNSX:MVMD. CN) (FRA:20MP) is pleased to announce that it confirmed the ability to make the drug ivermectin water-soluble without the use of organic solvents, which may enable the drug to be dosed by injection or inhalation in humans.
The Company believes the implications of this achievement will allow for significantly improved dosing by injection, orally consumed enteric coated capsules, and/or inhalation and, based on a recent ICON study (the "ICON Study"), may offer a potentially significant therapeutic in the fight against COVID-19. The ICON Study confirmed that the use of ivermectin is associated with a lower mortality in hospitalized COVID-19 patients despite being limited to an orally dosed tablet with poor bioavailability*, an issue that MVMD believes would be directly addressed with the Company's discovery.
Poor bioavailability? I'm unaware of that (doesn't mean it's not true).
Ivermectin is a well-documented anti parasitic drug being used globally in both veterinary and human medicine and its uses are being broadened to include such applications as an anti-malarial. Billons of world-wide doses annually are utilized in underdeveloped countries to protect most domestic and husbandry animals from parasites including poultry, pigs, cattle and horses. Ivermectin has documented limitations due to its poor solubility in water (. 005 mg/ml), thereby requiring the use of toxic organic solvents such as glycerol formal and ethanol, eliminating the possibility of FDA approval for a human injectable form or a more bio-available oral solution.
Chaccour et al used alcohol. Ivermectin solution is routinely used in Latin America; that's why Dr. Aguirre's dosing chart prescribes drops.
MVMD scientists, while working on improving the inclusion of ivermectin into the Company's patented Quicksome(TM) delivery system, made the discovery that they were able to make ivermectin highly water-soluble without the use of organic solvents, improving its water solubility by nearly 5,000 times. The Company believes that this result would eliminate the main limiter of the drug ivermectin** to achieve stronger pharmacokinetics and better overall efficacy.
Further, the new discovery uses only excipients that are currently approved by the US Food and Drug Administration (FDA). As the Company's strategy is to license its intellectual property to global pharmaceutical, vaccine and nutraceutical third parties, MVMD believes this discovery provides additional advantages to potential licensees as it may enable them to obtain FDA approvals more quickly based on there being fewer approval steps required for immediate applications in human and animal dosing.
An excipient is a substance formulated alongside the active ingredient of a medication, included for the purpose of long-term stabilization, bulking up solid formulations that contain potent active ingredients in small amounts (thus often referred to as "bulking agents", "fillers", or "diluents"),
According to The National Center for Biotechnology Information abstract dated October 7, 2020 (Ivermectin: an award-winning drug with expected antiviral activity against COVID-19), the potential for *ivermectin to be an antiviral agent for COVID-19 and other emerging viral diseases is based on the ability to overcome its property of poor water solubility and consequential low oral bioavailability. Appropriate drug formulations must address the poor water-solubility of ivermectin and the difficulty in delivering the drug to desired target areas, notably the pulmonary environment.
"We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery, " stated Mike Farber, Director of Life Sciences at Mountain Valley MD. "This will also allow ivermectin to be administered to humans via syringe and intravenous therapy, presenting what we believe are unprecedented options to provide treatment for numerous viruses. "
Aerosol would be a big win IMO.
According to Fior Market Research's (FMR) Global Ivermectin Medication Market Insights research report*, the COVID-19 virus has been found to impact the lungs of patients directly and cause inflammation to several organs. *Ivermectin medication has been used for treatment in various viruses such as RNA, Influenza A, Zika Virus, dengue, yellow fever, equine herpesvirus, new castle and others, which had similar symptoms on the human body as that of COVID-19. It has antiviral effects, which provides relief to slow down the effect of symptoms on the body. With several studies and research conducted on the potential contribution of ivermectin, it has been termed as an inhibitor of the SARS-COV-2 virus. The FRM report confirms ivermectin is a potential drug for the treatment of viruses, as only a single dose of it affects a 5000-fold reduction of viral RNA.
Additionally, FRM reports that a recent study has revealed that the use of ivermectin collectively with doxycycline effects the entry of viral in the body and clears a load of the virus by targeting the functional proteins. In the United States and certain other countries, an apparent high success rate of the patients who were given ivermectin medication was found. The recovery duration was also found to be shortened in some cases, along with relief in symptoms.
MVMD filed a patent application to cover all highly solublized macrocyclic lactones, including ivermectin and selamectin, which have also been shown to be effective in the treatment of tuberculosis even with limited solubility. The Company believes its solubility technology can dramatically enhance the efficacy of both inhaled and injected selamectin or ivermectin providing a novel effective therapeutic for tuberculosis. According to the World Health Organization*, tuberculosis is one of the top 10 causes of death and the leading cause from a single infectious agent globally.
"We believe the extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally, " stated Dennis Hancock, President & CEO of Mountain Valley MD. "We believe this will dramatically change the effectiveness and application options for numerous drugs on the market while also supporting the invention of novel drugs that are not limited based on their solubility. "
Maybe in time for covid21.
permalink